Evaluation of nitrendipine in reducing portal hypertension of patients with posthepatitic cirrhosis by nuclide rectum portal imaging
-
摘要: 选择钙通道阻滞剂尼群地平 ,对确诊为肝炎后硬化患者以99mTc -甲氧基异丁基异腈 (MIBI)直肠 -门脉显像法 ,无创性测定门脉压并做了用药前后的对比。用尼群地平 10mg ,每日二次 ,时间为一个月。结果显示用药前平均门脉压为x±s=(2 .994± 1.0 0 3)kPa,用药后门脉x±s=(2 .2 5 1± 0 .5 5 2 )kPa(P <0 .0 1)。结论 :钙通道阻滞剂尼群地平有明显降低门脉压作用。Abstract: WT5”BZ]:We measured portal tension of patients with posthepatitic cirrhosis before and after treated with nitrendipine and evaluated its curative effect in lowering portal hypertension by nuclide recturn portal imaging with 99m Tc MIBI.Method:Nitredipine 10mg 2/d.The course of treatment was one month.Result:The average portal tension was x±s= (2.994±1.003) kPa before giving drugs and x±s= (2.251±0.552) kPa after giving drugs (p<0.01) .Conclusion:Nitrendipine, a kind of calciumchannel blocking agent, can reduce hypertension distinctly. [WT5”HZ]
-
[1]齐桂英 , 冷希圣 , 高伯山 , 等 用心肝放射性比值推算门静脉压力的临床意义。中华医学杂志 , 1996, 5 -16 ( 2 ) ∶10 5 . [][2 ]ForsythOR , RobertsMD .Nitren dipineandrenaltubularfunctioninhumanvolunteersJClinPharmacol, 1992 , 3 2∶2 84.
本文二维码
计量
- 文章访问数: 2088
- HTML全文浏览量: 13
- PDF下载量: 22
- 被引次数: 0